Phathom Pharmaceuticals (PHAT) Projected to Post Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is expected to post its Q1 2026 results before the market opens on Thursday, April 30th. Analysts expect Phathom Pharmaceuticals to post earnings of ($0.17) per share and revenue of $58.6190 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, April 30, 2026 at 8:00 AM ET.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The firm had revenue of $57.58 million during the quarter, compared to analysts’ expectations of $57.44 million. On average, analysts expect Phathom Pharmaceuticals to post $0 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Phathom Pharmaceuticals Stock Up 3.7%

Shares of NASDAQ PHAT opened at $12.16 on Friday. The firm has a market cap of $965.87 million, a price-to-earnings ratio of -3.97 and a beta of 0.61. Phathom Pharmaceuticals has a 52-week low of $2.21 and a 52-week high of $18.31. The business’s 50 day moving average is $11.58 and its two-hundred day moving average is $13.42.

Institutional Trading of Phathom Pharmaceuticals

Large investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Phathom Pharmaceuticals during the fourth quarter worth $27,000. Kestra Advisory Services LLC purchased a new stake in shares of Phathom Pharmaceuticals during the fourth quarter worth $38,000. Raymond James Financial Inc. purchased a new stake in shares of Phathom Pharmaceuticals during the second quarter worth $30,000. BNP Paribas Financial Markets increased its position in shares of Phathom Pharmaceuticals by 71.9% during the second quarter. BNP Paribas Financial Markets now owns 5,072 shares of the company’s stock worth $49,000 after acquiring an additional 2,122 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in shares of Phathom Pharmaceuticals by 58.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,710 shares of the company’s stock worth $55,000 after acquiring an additional 2,102 shares during the period. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Barclays raised Phathom Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $16.00 to $18.00 in a research report on Friday, March 27th. Stifel Nicolaus set a $28.00 target price on Phathom Pharmaceuticals in a research report on Thursday, February 26th. Guggenheim boosted their target price on Phathom Pharmaceuticals from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Phathom Pharmaceuticals in a research report on Wednesday, January 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.